SCHEMBL23923538

SCHEMBL23923538

CCC(C)(O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.54
CYP4F2 P78329 1/20 0.51
CYP4A11 Q02928 1/20 0.51
BCHE P06276 3/20 0.50
NR4A2 P43354 2/20 0.50
PKM P14618 1/20 0.50
CACNA1B Q00975 1/20 0.49
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
NR4A1 P22736 1/20 0.49
NR4A3 Q92570 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.48
MAOA P21397 1/20 0.47
ACSS2 Q9NR19 1/20 0.46
SMPD1 P17405 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9434943 0.86 MAOB (0.58) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL10854965 0.86 MAOB (0.49) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL10664905 0.85 MAOB (0.48) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL13930902 0.85 MAOB (0.57) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL3442750 0.85 CACNA1B (0.52) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL11046795 0.84 MAOB (0.47) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL9022828 0.83 CYP4F2 (0.52) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL12251480 0.83 TP53 (0.49) ACSS2
SCHEMBL78171 0.83 MAOB (0.62) MAOBCYP4F2CYP4A11BCHENR4A2
SCHEMBL3442748 0.82 PKM (0.54) MAOBNR4A2PKMCACNA1BPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010912-A Antiviral 1, 3-dioxoindene compounds 诺华股份有限公司 2026-05-12 CN disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 CN disclosed
EP-4139301-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 EP disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 WO disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 WO disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 MAOB 2196/4885CYP4F2 1660/4885CYP4A11 714/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 MAOB 2196/4885CYP4F2 1660/4885CYP4A11 714/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 MAOB 2196/4885CYP4F2 1660/4885CYP4A11 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.